Abstract
Mood disorders, such as major depressive disorder and bipolar disorder, are common, severe and chronic psychiatric diseases. There is an increasing recognition that the pathophysiology of mood disorders could be the result of dysregulation of synaptic plasticity with alterations in the levels of neurotrophins. Brain-derived neurotrophic factor (BDNF), the most abundant neurotrophin in the brain, has been investigated extensively in mood disorder. BDNF is important for neuronal growth, development, differentiation and survival. In addition, BDNF can modulate synaptic plasticity and its molecular mediators across multiple neurotransmitter systems, as well as the intracellular signal-transduction pathway. From findings in animal as well as clinical studies, the BDNF gene is considered an attractive candidate for predicting mood disorders or antidepressant/mood stabilizer therapeutic response. In this review, we summarize the findings of recent investigations of the effects of the BDNF gene on therapeutic response and the risk for mood disorders. Although the general conclusion to be drawn from the findings of these genetic studies, is that BDNF genetic variants have implications for the pathogenesis and treatment of mood disorders, the findings of these studies are sometimes inconsistent. Several recommendations are proposed for future genetic studies of BDNF signaling pathways in mood disorders.
Keywords: Bipolar disorder, brain-derived neurotrophic factor, major depression, polymorphism, antidepressant
Current Pharmacogenomics and Personalized Medicine
Title: Effect of Brain-Derived Neurotrophic Factor (BDNF) Gene Variants on the Therapeutic Response and the Risk for Mood Disorders
Volume: 6
Author(s): Shih-Jen Tsai and Chen-Jee Hong
Affiliation:
Keywords: Bipolar disorder, brain-derived neurotrophic factor, major depression, polymorphism, antidepressant
Abstract: Mood disorders, such as major depressive disorder and bipolar disorder, are common, severe and chronic psychiatric diseases. There is an increasing recognition that the pathophysiology of mood disorders could be the result of dysregulation of synaptic plasticity with alterations in the levels of neurotrophins. Brain-derived neurotrophic factor (BDNF), the most abundant neurotrophin in the brain, has been investigated extensively in mood disorder. BDNF is important for neuronal growth, development, differentiation and survival. In addition, BDNF can modulate synaptic plasticity and its molecular mediators across multiple neurotransmitter systems, as well as the intracellular signal-transduction pathway. From findings in animal as well as clinical studies, the BDNF gene is considered an attractive candidate for predicting mood disorders or antidepressant/mood stabilizer therapeutic response. In this review, we summarize the findings of recent investigations of the effects of the BDNF gene on therapeutic response and the risk for mood disorders. Although the general conclusion to be drawn from the findings of these genetic studies, is that BDNF genetic variants have implications for the pathogenesis and treatment of mood disorders, the findings of these studies are sometimes inconsistent. Several recommendations are proposed for future genetic studies of BDNF signaling pathways in mood disorders.
Export Options
About this article
Cite this article as:
Tsai Shih-Jen and Hong Chen-Jee, Effect of Brain-Derived Neurotrophic Factor (BDNF) Gene Variants on the Therapeutic Response and the Risk for Mood Disorders, Current Pharmacogenomics and Personalized Medicine 2008; 6 (2) . https://dx.doi.org/10.2174/1875692110806020126
DOI https://dx.doi.org/10.2174/1875692110806020126 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Plant Polyphenols as Neuroprotective Agents in Parkinson’s Disease Targeting Oxidative Stress
Current Drug Targets Raman Spectroscopy-based Metabonomics of HIV-infected Sera Detects Amino Acid and Glutathione Changes
Current Metabolomics Pilot Randomized Controlled Study of a Histamine Receptor Inverse Agonist in the Symptomatic Treatment of AD
Current Alzheimer Research α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer's Disease
Current Alzheimer Research Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Genetic Studies in Relation to Kuru: An Overview
Current Molecular Medicine Cognitive Impairment and Dementia in Patients with Parkinson Disease
Current Topics in Medicinal Chemistry 6-Benzothiazolyl Ureas, Thioureas and Guanidines are Potent Inhibitors of ABAD/17β-HSD10 and Potential Drugs for Alzheimer"s Disease Treatment: Design, Synthesis and in vitro Evaluation
Medicinal Chemistry EDITORIAL: Neuroprotection Mechanisms and their Potential Applications
Current Neuropharmacology DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research Separation and Purification of Small Peptides from Fermented Sesame Meal and Their Antioxidant Activities
Protein & Peptide Letters Beneficial Effects of Lysosome-Modulating and Other Pharmacological and Nanocarrier Agents on Amyloid-beta-treated Cells
Current Pharmaceutical Biotechnology Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) Editorial [ Proteases and Phospholipases in CNS Disorders Guest Editor: Swapan K. Ray ]
CNS & Neurological Disorders - Drug Targets